Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.

Heidebrecht HJ, Weiss WJ, Pulse M, Lange A, Gisch K, Kliem H, Mann S, Pfaffl MW, Kulozik U, von Eichel-Streiber C.

Toxins (Basel). 2019 Feb 6;11(2). pii: E98. doi: 10.3390/toxins11020098.


The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.


Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.


Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.


SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

Sattar A, Thommes P, Payne L, Warn P, Vickers RJ.

J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3.


Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.

Tian JH, Glenn G, Flyer D, Zhou B, Liu Y, Sullivan E, Wu H, Cummings JF, Elllingsworth L, Smith G.

Vaccine. 2017 Jul 24;35(33):4079-4087. doi: 10.1016/j.vaccine.2017.06.062. Epub 2017 Jun 29.


Mouse relapse model of Clostridium difficile infection.

Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H.

Infect Immun. 2011 Jul;79(7):2856-64. doi: 10.1128/IAI.01336-10. Epub 2011 May 16.


Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.

Freeman J, Marquis M, Crowther GS, Todhunter SL, Fawley WN, Chilton CH, Moeck G, Lehoux D, Wilcox MH.

J Antimicrob Chemother. 2012 Dec;67(12):2919-26. doi: 10.1093/jac/dks309. Epub 2012 Aug 16.


Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer JL, Heinrichs JH, Secore S.

Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.


Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.

Wang Y, Wang S, Bouillaut L, Li C, Duan Z, Zhang K, Ju X, Tzipori S, Sonenshein AL, Sun X.

Infect Immun. 2018 Oct 25;86(11). pii: e00489-18. doi: 10.1128/IAI.00489-18. Print 2018 Nov.


Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Anton PM, O'Brien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2004 Oct;48(10):3975-9.


The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.

Džunková M, D'Auria G, Xu H, Huang J, Duan Y, Moya A, Kelly CP, Chen X.

Front Cell Infect Microbiol. 2016 Oct 4;6:119. eCollection 2016.


Best strategies in recurrent or persistent Clostridium difficile infection.

Cocanour CS.

Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18. Review.


Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.

Hutton ML, Cunningham BA, Mackin KE, Lyon SA, James ML, Rood JI, Lyras D.

Sci Rep. 2017 Jun 16;7(1):3665. doi: 10.1038/s41598-017-03982-5.


Characterization of Chicken IgY Specific to Clostridium difficile R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Disease.

Pizarro-Guajardo M, Díaz-González F, Álvarez-Lobos M, Paredes-Sabja D.

Front Cell Infect Microbiol. 2017 Aug 14;7:365. doi: 10.3389/fcimb.2017.00365. eCollection 2017.


Establishment of an Endogenous Clostridium difficile Rat Infection Model and Evaluation of the Effects of Clostridium butyricum MIYAIRI 588 Probiotic Strain.

Oka K, Osaki T, Hanawa T, Kurata S, Sugiyama E, Takahashi M, Tanaka M, Taguchi H, Kamiya S.

Front Microbiol. 2018 Jun 18;9:1264. doi: 10.3389/fmicb.2018.01264. eCollection 2018.


Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.

von Eichel-Streiber A, Paik W, Knight K, Gisch K, Nadjafi K, Decker C, Bosnjak O, Cheknis A, Johnson S, von Eichel-Streiber C.

Anaerobe. 2016 Oct;41:91-103. doi: 10.1016/j.anaerobe.2016.07.001. Epub 2016 Jul 15.


Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.

Carter GP, Chakravorty A, Pham Nguyen TA, Mileto S, Schreiber F, Li L, Howarth P, Clare S, Cunningham B, Sambol SP, Cheknis A, Figueroa I, Johnson S, Gerding D, Rood JI, Dougan G, Lawley TD, Lyras D.

MBio. 2015 Jun 2;6(3):e00551. doi: 10.1128/mBio.00551-15.


Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.

Buckley AM, Spencer J, Maclellan LM, Candlish D, Irvine JJ, Douce GR.

PLoS One. 2013 May 21;8(5):e64121. doi: 10.1371/journal.pone.0064121. Print 2013.

Supplemental Content

Support Center